Trending with Impact: MEND Study Analysis of Nigerian Breast Cancer

1 views

|

August 11, 2021

Oncotarget published this trending research perspective on June 22, 2021, entitled, "Association of high-sensitivity C-reactive protein and odds of breast cancer by molecular subtype: analysis of the MEND study" by researchers from Duke University, Durham, NC; University of Lagos, Lagos State, Nigeria; Obafemi Awolowo University Teaching Hospital, Ile-Ife, Osun State, Nigeria; University College Hospital, University of Ibadan, Ibadan, Oyo State, Nigeria; Federal Medical Center, Abeokuta, Ogun State, Nigeria; UNC Gillings School of Global Public Health, Chapel Hill, NC; Our Lady of Apostle Catholic Hospital, Ibadan, Oyo State, Nigeria; University of Alabama at Birmingham, AL; University of Kentucky, Lexington, KY; University of Kansas Medical Center, Kansas City, KS. Abstract: Breast cancer (BC) in Nigeria is characterized by disproportionately aggressive molecular subtypes. C-reactive protein (CRP) is associated with risk and aggressiveness for several types of cancer. We examined the association of high-sensitivity CRP (hsCRP) with odds of BC by molecular subtype among Nigerian women. Among 296 newly diagnosed BC cases and 259 healthy controls, multivariable logistic regression models were used to estimate adjusted odds ratios (aOR) and 95% confidence intervals (CI) for the association between hsCRP and odds of BC overall and by molecular subtype (luminal A, luminal B, HER2-enriched and triple-negative or TNBC). High hsCRP (> 3 mg/L) was observed in 57% of cases and 31% of controls and was associated with 4 times the odds of BC (aOR: 4.43; 95% CI: 2.56, 7.66) after adjusting for socio-demographic, reproductive, and clinical variables. This association persisted regardless of menopausal status and body mass index (BMI) category. High hsCRP was associated with increased odds of TNBC (aOR: 3.32; 95% CI: 1.07, 10.35), luminal A BC (aOR: 4.03; 95% CI: 1.29, 12.64), and HER2-enriched BC (aOR: 6.27; 95% CI: 1.69, 23.25). Future studies are necessary in this population to further evaluate a potential role for CRP as a predictive biomarker for BC. Press release - https://www.oncotarget.com/news/pr/oncotarget-odds-of-breast-cancer-by-molecular-subtype-analysis-of-the-mend-study/ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27991 DOI - https://doi.org/10.18632/oncotarget.27991 Full text - https://www.oncotarget.com/article/27991/text/ Correspondence to - Tomi Akinyemiju - tomi.akinyemiju@duke.edu Keywords - C-reactive protein, breast cancer, Nigeria, molecular subtype, menopausal status About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget YouTube - https://www.youtube.com/c/OncotargetYouTube/ LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957

Cancer Research

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.